<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049464</url>
  </required_header>
  <id_info>
    <org_study_id>Si628/2009</org_study_id>
    <nct_id>NCT01049464</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate for Treatment of New Onset Atrial Fibrillation in Medical Intensive Care Unit Patient</brief_title>
  <acronym>EMSAF</acronym>
  <official_title>Efficacy of Magnesium Sulphate for Rate and Rhythm Control of New-onset Atrial Fibrillation in the Medical Critically Ill Patients: A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of Magnesium sulphate for the rate and&#xD;
      rhythm control of the new onset (within 48 hours) atrial fibrillation in the hemodynamically&#xD;
      unstable patients, admitted in the medical intensive care unit patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is one of the most common arrhythmia, reported in the hemodynamically&#xD;
      unstable patients in the intensive care unit. Loss of atrial contraction and the sequential&#xD;
      atrioventricular contraction decrease the overall cardiac output which results in severe&#xD;
      inadequate tissue perfusion. Medications aim for rate and rhythm control are recommended to&#xD;
      treat new onset atrial fibrillation. These drugs (verapamil, diltiazem, amiodarone and beta&#xD;
      blockers) may further compromise the patients' cardiac output by its' negative inotropic&#xD;
      effect.&#xD;
&#xD;
      Magnesium sulphate with the cell membrane threshold potential stabilizing effect has been&#xD;
      reported as an effective drug for rate and rhythm control for post-operative atrial&#xD;
      fibrillation and the atrial fibrillation presented in the hospital emergency unit. However,&#xD;
      there was inadequate data about the efficacy of Magnesium sulphate for treatment of new onset&#xD;
      atrial fibrillation in the hemodynamically unstable patients admitted in the medical&#xD;
      intensive care unit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of conversion to sinus rhythm and/or ventricular rate less than 120 beats per min</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure, superior vena cava or mixed venous oxygen saturation, cardiac index, inotropic and vasopressors dosage</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>5%D/W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.</description>
    <arm_group_label>5%D/W</arm_group_label>
    <other_name>5%D/W</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.</description>
    <arm_group_label>Magnesium sulphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted in medical intensive care unit&#xD;
&#xD;
          -  Age 18 years or more&#xD;
&#xD;
          -  New onset atrial fibrillation (within 48 hours), persist for at least 1 hour,&#xD;
             ventricular rate 120 beats per min or more without evidence of volume depletion (CVP 8&#xD;
             mmHg or more or receive volume resuscitation about 20-30 ml/kg), oxygen saturation not&#xD;
             less than 90%, serum Potassium level between 3.0-5.0 mEq/l, serum Calcium level&#xD;
             between 8.0-11.0 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic atrial fibrillation&#xD;
&#xD;
          -  Severe valvular heart disease including severe mitral regurgitation, mitral stenosis,&#xD;
             aortic regurgitation, aortic stenosis, tricuspid regurgitation, tricuspid stenosis,&#xD;
             pulmonic regurgitation or pulmonic stenosis&#xD;
&#xD;
          -  Indicated for electrical cardioversion&#xD;
&#xD;
          -  Severe hypomagnesemia (serum Magnesium &lt; 1.2 mg/dl)&#xD;
&#xD;
          -  Severe hypermagnesemia (serum Magnesium &gt; 5.0 mg/dl)&#xD;
&#xD;
          -  Renal insufficiency with creatinine &gt; 3.0 mg/dl without renal replacement therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Surat Tongyoo, MD</last_name>
    <phone>6624198534</phone>
    <email>surat_Ty@yahoo.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surat Tongyoo, MD</last_name>
      <phone>6624198534</phone>
      <email>surat_Ty@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Surat Tongyoo</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Hemodynamically unstable patients</keyword>
  <keyword>Magnesium sulfate</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Medical intensive care unit</keyword>
  <keyword>New onset atrial fibrillation</keyword>
  <keyword>Critically ill patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

